AfghanistanTuberculosis profile
Population  2015 33 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 12 (7.1–18) 37 (22–55)
Mortality (HIV+TB only) 0.17 (0.14–0.21) 0.53 (0.44–0.63)
Incidence  (includes HIV+TB) 61 (40–88) 189 (122–270)
Incidence (HIV+TB only) 0.46 (0.28–0.68) 1.4 (0.86–2.1)
Incidence (MDR/RR-TB)** 3 (1.8–4.1) 9.2 (5.5–13)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 3.8 (1.5–6) 30 (19–40) 33 (21–46)
Males 4 (2.3–5.6) 24 (16–32) 28 (19–37)
Total 7.8 (4.9–11) 54 (40–67) 61 (40–88)
TB case notifications, 2015  
Total cases notified 37 001
Total new and relapse 35 878
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 39%
          - % pulmonary 75%
          - % bacteriologically confirmed among pulmonary 66%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 58% (41–90)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.21 (0.11–0.36)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 3 <1%
          - on antiretroviral therapy 3 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 400
(1 100–1 600)
Estimated % of TB cases with MDR/RR-TB 3.9% (2.9–5) 16% (12–19)  
% notified tested for rifampicin resistance 0% 4% 81
MDR/RR-TB cases tested for resistance to second-line drugs   1
Laboratory-confirmed cases MDR/RR-TB: 81, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 81, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 87% 31 746
Previously treated cases, excluding relapse, registered in 2014 80% 966
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 63% 46
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 81%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
58% (53–63)
TB financing, 2016  
National TB budget (US$ millions) 13
Funding source: 7% domestic, 83% international, 10% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-01-24 Data: www.who.int/tb/data